Biotech Sector Response to Economic Changes: Biotech and healthcare stocks are reacting positively to the Federal Reserve's first rate cut of 2025, which is expected to improve funding conditions for capital-intensive sectors like biotechnology. Companies are experiencing notable price movements due to clinical trial progress and regulatory developments.
Sonnet BioTherapeutics Update: Sonnet BioTherapeutics' shares rose significantly after announcing expanded clinical evaluation of its lead candidate for ovarian cancer, along with a strong safety profile and partial response results. Key upcoming events include a stockholder meeting and trial updates.
Akari Therapeutics Patent Filing: Akari Therapeutics saw a surge in its stock price following a provisional patent filing for its antibody-drug conjugate platform aimed at cancer treatment, which enhances its intellectual property and supports the development of innovative therapies.
Reviva Pharmaceuticals and Cognition Therapeutics Developments: Reviva Pharmaceuticals' stock increased after a revised analyst rating maintained confidence in its long-term potential, while Cognition Therapeutics announced a $30 million offering to support its Alzheimer's treatment candidate, Zervimesine, which is progressing towards Phase 3 development.
Wall Street analysts forecast RVPH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RVPH is 5.14 USD with a low forecast of 2.00 USD and a high forecast of 16.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
Wall Street analysts forecast RVPH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RVPH is 5.14 USD with a low forecast of 2.00 USD and a high forecast of 16.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Buy
0 Hold
0 Sell
Strong Buy
Current: 0.350
Low
2.00
Averages
5.14
High
16.00
Current: 0.350
Low
2.00
Averages
5.14
High
16.00
Roth Capital
Buy
downgrade
$3
Al Analysis
2025-12-23
Reason
Roth Capital
Price Target
$3
Al Analysis
2025-12-23
downgrade
Buy
Reason
Roth Capital lowered the firm's price target on Reviva Pharmaceuticals to $1.50 from $3 and keeps a Buy rating on the shares after the company's request to file an NDA without a second Phase 3 schizophrenia study was denied by the FDA. While "disappointed" about today's update, the firm notes that its base case scenario assumed a second Phase 3 study would be needed. The firm remains "optimistic" about brilaroxazine, but lowers its price target in anticipation of equity dilution as it notes that the company requires about $60M to $75M to execute the second Phase 3 study.
H.C. Wainwright
Buy
downgrade
$11 -> $4
2025-10-27
Reason
H.C. Wainwright
Price Target
$11 -> $4
2025-10-27
downgrade
Buy
Reason
H.C. Wainwright lowered the firm's price target on Reviva Pharmaceuticals to $4 from $11 and keeps a Buy rating on the shares. The firm cites the company's two "highly dilutive" financing transactions in June and September for the target cut.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for RVPH
Unlock Now
Chardan
NULL -> Buy
initiated
$2
2025-09-29
Reason
Chardan
Price Target
$2
2025-09-29
initiated
NULL -> Buy
Reason
Chardan initiated coverage of Reviva Pharmaceuticals with a Buy rating and $2 price target. The firm cites the potential of the company's lead asset brilaroxazine as a next-generation antipsychotic product for the Buy rating. Reviva's brilaroxazine is a \"real product\" that could get approval in schizophrenia and find a niche in a large but highly genericized market, the analyst tells investors in a research note.
D. Boral Capital
Jason Kolbert
Buy
downgrade
$3 -> $2
2025-09-19
Reason
D. Boral Capital
Jason Kolbert
Price Target
$3 -> $2
2025-09-19
downgrade
Buy
Reason
D. Boral Capital analyst Jason Kolbert lowered the firm's price target on Reviva Pharmaceuticals to $2 from $3 and keeps a Buy rating on the shares. The company has executed on back-to-back capital raises that provide $19M in gross proceeds and reinforce its near-term financial runway, the analyst tells investors in a research note. The firm says that while Reviva's balance sheet is strengthened, the company's dilution overhang has expanded.
About RVPH
Reviva Pharmaceuticals Holdings, Inc. is a late-stage pharmaceutical company. The Company discovers, develops, and seeks to commercialize therapeutics for diseases representing unmet medical needs. The Company’s pipeline focuses on the central nervous system, inflammatory, and cardiometabolic diseases. Its pipeline includes two drug candidates, brilaroxazine (RP5063) and RP1208. Its lead drug candidate, brilaroxazine, is in clinical development and is to treat multiple neuropsychiatric indications. These include schizophrenia, bipolar disorder (BD), major depressive disorder (MDD), attention-deficit/hyperactivity disorder (ADHD), behavioral and psychotic symptoms of dementia or Alzheimer’s disease (BPSD), and Parkinson’s disease psychosis. Brilaroxazine is also ready for clinical development for two respiratory indications, including pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF). Its RP1208 drug candidate is a triple reuptake inhibitor (TRI).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
